Who
Nick Pizzie
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Axsome Therapeutics.
In numbers
- Trades disclosed
- 52
- Buys
- 6
- Sells
- 4
- Bought
- $351K
- Sold
- $22.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 16 May 2018
- Last trade
- 9 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 9 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $116K33,000 at $3.50 | filing |
| 9 Jun 2026filed 9 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $7.9M33,000 at $240.09 | filing |
| 9 Jun 2026filed 9 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,000 at $0.00 | filing |
| 9 Jun 2026filed 9 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,000 at $0.00 | filing |
| 9 Jun 2026filed 9 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $116K33,000 at $3.50 | filing |
| 9 Jun 2026filed 9 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $7.9M33,000 at $240.09 | filing |
| 21 Apr 2026filed 23 Apr 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,188 at $0.00 | filing |
| 21 Apr 2026filed 23 Apr 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,188 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,570 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,570 at $0.00 | filing |
| 22 Jan 2026filed 23 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $42K12,000 at $3.50 | filing |
| 22 Jan 2026filed 23 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.3M12,000 at $187.92 | filing |
| 22 Jan 2026filed 23 Jan 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 22 Jan 2026filed 23 Jan 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 22 Jan 2026filed 23 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | $42K12,000 at $3.50 | filing |
| 22 Jan 2026filed 23 Jan 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.3M12,000 at $187.92 | filing |
| 24 Feb 2025filed 25 Feb 2025 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,423 at $0.00 | filing |
| 21 Feb 2025filed 25 Feb 2025 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,516 at $0.00 | filing |
| 21 Feb 2025filed 25 Feb 2025 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,423 at $0.00 | filing |
| 14 Feb 2025filed 14 Feb 2025 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $11K3,000 at $3.50 | filing |
News
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?AXSM · fool.com · 8 Oct 2026
0 headlines in the last 90 days name Nick Pizzie; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.